Uli Hacksell Net Worth

The estimated Net Worth of Uli Hacksell is at least $58.6 Mille dollars as of 10 December 2016. Uli Hacksell owns over 20,000 units of Cerecor Inc stock worth over $58,600 and over the last 20 years Uli sold CERC stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Uli Hacksell CERC stock SEC Form 4 insiders trading

Uli has made over 22 trades of the Cerecor Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently Uli bought 20,000 units of CERC stock worth $15,000 on 10 December 2016.

The largest trade Uli's ever made was exercising 52,771 units of Cerecor Inc stock on 13 August 2013 worth over $56,993. On average, Uli trades about 10,318 units every 30 days since 2004. As of 10 December 2016 Uli still owns at least 20,000 units of Cerecor Inc stock.

You can see the complete history of Uli Hacksell stock trades at the bottom of the page.

What's Uli Hacksell's mailing address?

Uli's mailing address filed with the SEC is C/O CERECOR INC., 540 GAITHER ROAD, SUITE 400, ROCKVILLE, MD, 20850.

Insiders trading at Cerecor Inc

Over the last 9 years, insiders at Cerecor Inc have traded over $0 worth of Cerecor Inc stock and bought 18,463,844 units worth $43,946,959 . The most active insiders traders include Forest Baskett, Scott D Sandell e Capital, Llc Armistice Capi.... On average, Cerecor Inc executives and independent directors trade stock every 19 days with the average trade being worth of $601,142. The most recent stock trade was executed by Capital, Llc Armistice Capi... on 16 August 2021, trading 50,000 units of CERC stock currently worth $138,000.

What does Cerecor Inc do?

Cerecor is a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare and orphan diseases. The company is advancing its clinical-stage pipeline of innovative therapies that address unmet patient needs within rare and orphan diseases. The company's rare disease pipeline includes CERC-801, CERC-802 and CERC-803, which are in development for congenital disorders of glycosylation and CERC-006, an oral mTORc1/c2 inhibitor in development for the treatment of complex lymphatic malformations. The company is also developing two monoclonal antibodies, CERC-002, and CERC-007. CERC-002 targets the cytokine LIGHT (TNFSF14) and is in clinical development for treatment of severe pediatric-onset Crohn's disease, and COVID-19 acute respiratory distress syndrome. CERC-007 targets the cytokine IL-18 and is in clinical development for the treatment of Still's disease (adult onset Still's disease (AOSD) and systemic juvenile idiopathic arthritis (sJIA)), and multiple myeloma (MM). CERC-006, 801, 802 and 803 have all received Orphan Drug Designation and Rare Pediatric Disease Designation, which makes all four eligible for a priority review voucher upon FDA approval.

Complete history of Uli Hacksell stock trades at Acadia Pharmaceuticals Inc e Cerecor Inc

Cerecor Inc executives and stock owners

Cerecor Inc executives and other stock owners filed with the SEC include:

• Joseph Miller,
  Director
• Jamie Harrell,
  Chief Commercial Officer
• Phil Gutry,
  Independent Director
• Magnus Persson,
  Independent Director
• Gilla Kaplan,
  Independent Director
• Steven Boyd,
  Independent Director
• Suzanne Bruhn,
  Director
• Jeff Wilkins,
  Chief Development Officer
• Garry Neil,
  Chief Scientific Officer
• Christopher Sullivan,
  Interim Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer
• Michael Cola,
  Chief Executive Officer, Director
• Sol Barer,
  Chairman of the Board
• Thomas H Aasen,
  Director
• Mariam E Morris,
  Chief Financial Officer
• Ronald Marcus,
  Chief Medical Officer
• John Joseph Kaiser,
  Chief Business Officer
• Eugene A Bauer,
  Director
• Robert Jr. Moscato,
  Director
• Peter Greenleaf,
  Director
• Keith Schmidt,
  Director
• Pericles Calias,
  Chief Scientific Officer
• Matthew V Phillips,
  Chief Commercial Officer
• Randal Jones,
  Director
• Patrick J Crutcher,
  VP, Business Development
• Robert Jr.Lrs International...,
  
• Randal Fremantle, Llc Jones,
  
• Capital, Llc Boyd Steven Ar...,
  
• Simon Pedder,
  Executive Chairman of the Bd
• Uli Hacksell,
  Director
• Tree Partners Iv, L.P.Atp I...,
  
• David M Mott,
  10% owner
• Behshad Sheldon,
  Director
• Anthony A. Jr. Florence,
  10% owner
• Krishna Kittu Kolluri,
  10% owner
• Peter W. Sonsini,
  10% owner
• Harry R Weller,
  10% owner
• Blake M Paterson,
  CEO and President
• Forest Baskett,
  10% owner
• Ravi Viswanathan,
  10% owner
• M James Barrett,
  10% owner
• Scott D Sandell,
  10% owner
• Enterprise Associates 14, L...,
  
• Bioventures V, L.P.Mpm Asse...,
  
• Peter J Barris,
  10% owner
• Patrick J Kerins,
  10% owner
• Isaac Blech,
  Director
• James Archie Jr Harrell,
  Chief Commercial Officer
• Schond L. Greenway,
  CFO